Skip to main content

Table 1 Patient characteristics

From: Barriers in phase I cancer clinical trials referrals and enrollment: five-year experience at the Princess Margaret Hospital

Age Mean (sd) 56.5 (11.1)
Distance from PMH (km) Median (range) [IQR] 22.2 (0.6–1480.2) [12.7–42.7]
Gender Male:Female 339:328 (50.8:49.2)
Tumor site Breast 46 (6.9)
  GI colorectal 172 (25.8)
  GI non-colorectal 178 (26.7)
  Genitourinary 36 (5.4)
  Gynaecologic 74 (11.1)
  Head and neck 23 (3.5)
  Lung 57 (8.6)
  Sarcoma 8 (1.2)
  Skin and melanoma 11 (1.7)
  Unknown primary 42 (6.3)
  Multiple sites* 6 (0.9)
  Other** 14 (2.1)
Number of prior regimens 0 68 (10.2)
  1 210 (31.5)
  2 186 (27.9)
  3 116 (17.4)
  4 52 (7.8)
  5 24 (3.6)
  6+ 11 (1.7)
PS 0 211 (31.6)
  1 318 (47.7)
  2 87 (13.0)
  3 49 (7.4)
  4 2 (0.3)
Entered on trial Yes:No 197:470 (29.5:70.5)
Referring physician PMH Oncologist 328 (49.2)
  External Oncologist 310 (46.5)
  Family Physician 12 (1.8)
  Other Physician 13 (2.0)
  Unknown 4 (0.6)
  1. * Multiple sites were GI non-colorectal/gastric/lymphoma, GI non-colorectal/prostate, lung/breast, lung/esophageal, skin and melanoma/leukemia, unknown/prostate
  2. ** Others were adrenal [1], GI stromal [1], lymphoma [2], merkel cell [1] mesothelioma [3], mixed germ cell [1], neuroendocrine [2], pseudomyxoma [1], thyroid [1] and thymus [1]